Antitumor cytostatic doxorubicin in liposomal form does not have a damaging effect on mitochondria
- Authors: Nikitina E.R1, Korotkov S.M1, Petunov S.G1, Vasileva K.A1, Mindukshev I.V1, Krivchenko A.I1
-
Affiliations:
- Sechenov Institute of evolutionary physiology and biochemistry RAS
- Issue: Vol 14, No 3 (2019)
- Pages: 85-86
- Section: Articles
- URL: https://genescells.ru/2313-1829/article/view/122419
- DOI: https://doi.org/10.23868/gc122419
- ID: 122419
Cite item
Open Access
Access granted
Abstract
Full Text
About the authors
E. R Nikitina
Sechenov Institute of evolutionary physiology and biochemistry RAS
Email: elena.nikitina@bk.ru
St. Petersburg, Russia
S. M Korotkov
Sechenov Institute of evolutionary physiology and biochemistry RASSt. Petersburg, Russia
S. G Petunov
Sechenov Institute of evolutionary physiology and biochemistry RASSt. Petersburg, Russia
K. A Vasileva
Sechenov Institute of evolutionary physiology and biochemistry RASSt. Petersburg, Russia
I. V Mindukshev
Sechenov Institute of evolutionary physiology and biochemistry RASSt. Petersburg, Russia
A. I Krivchenko
Sechenov Institute of evolutionary physiology and biochemistry RASSt. Petersburg, Russia
References
- Forrancs V.J. Overview of cardiac pathology in relation to anthracydine cardiac toxicity. Canc. Treat. Rep. 1978; 62: 955-61.
- Olson R.D., Mushlin P.S., Brenner D.E. et al. Doxorubicin cardio-toxicity may be caused by its metabolite, doxorubicinol. PNAS USA 1988; 85(10): 3585-9.
- Harrington K.L., Lewanski C.R., Stewart S.W. Liposomes as vehicles for targeted therapy of cancer. Part 2: Clinical development. Clin. Oncol. 2000; 12: 16-24.
Supplementary files
